138 related articles for article (PubMed ID: 37340883)
21. Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.
Huang F; Tang J; Lou J; Wang Q; Ma K; Qiao R; Si J; Kang Y; Chen H; Mei J; Wang H; Liu Y; Miao L
Transl Cancer Res; 2022 Sep; 11(9):3337-3342. PubMed ID: 36237231
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
[TBL] [Abstract][Full Text] [Related]
23. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
[TBL] [Abstract][Full Text] [Related]
25. Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report.
Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
Front Oncol; 2022; 12():980842. PubMed ID: 36033531
[TBL] [Abstract][Full Text] [Related]
26. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
28. A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy.
Zhang B; Tang K; Dong X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):578-582. PubMed ID: 37899397
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
30. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol.
Wang Y; Wang X; Guan Y; Song Y; Zhuang H; Wang E
Thorac Cancer; 2020 May; 11(5):1361-1364. PubMed ID: 32163662
[TBL] [Abstract][Full Text] [Related]
32. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
33. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
35. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review.
Zuo R; Zhang C; Lin L; Meng Z; Wang Y; Su Y; Abudurazik M; Du Y; Chen P
Thorac Cancer; 2020 Nov; 11(11):3383-3387. PubMed ID: 32997432
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.
Tao Y; Han J; Li Y
Invest New Drugs; 2022 Aug; 40(4):854-857. PubMed ID: 35503192
[TBL] [Abstract][Full Text] [Related]
37. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
38. A case report of carcinoma of uterine cervix throwing heterochronous metastasis to the skin, spleen, and pancreas: the role of multimodality treatment approach.
Gupta PK; Lal P; Tiwari A
J Egypt Natl Canc Inst; 2019 Dec; 31(1):8. PubMed ID: 32372163
[TBL] [Abstract][Full Text] [Related]
39. Anlotinib: First Global Approval.
Syed YY
Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
[TBL] [Abstract][Full Text] [Related]
40. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]